Avanos Medical, Inc. (NYSE:AVNS) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Avanos Medical, Inc. (NYSE:AVNS) by 58.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,668 shares of the company’s stock after acquiring an additional 16,929 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.10% of Avanos Medical worth $1,097,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Tidal Investments LLC acquired a new position in Avanos Medical in the first quarter worth about $439,000. Boston Partners acquired a new position in Avanos Medical in the first quarter worth about $571,000. Azzad Asset Management Inc. ADV grew its stake in Avanos Medical by 8.5% in the second quarter. Azzad Asset Management Inc. ADV now owns 28,521 shares of the company’s stock worth $568,000 after purchasing an additional 2,223 shares in the last quarter. Natixis Advisors LLC grew its stake in Avanos Medical by 19.5% in the second quarter. Natixis Advisors LLC now owns 18,878 shares of the company’s stock worth $376,000 after purchasing an additional 3,077 shares in the last quarter. Finally, Paradice Investment Management LLC grew its stake in Avanos Medical by 5.4% in the second quarter. Paradice Investment Management LLC now owns 1,344,949 shares of the company’s stock worth $26,791,000 after purchasing an additional 69,389 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Avanos Medical Stock Performance

Shares of NYSE AVNS opened at $19.14 on Thursday. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. The firm’s 50-day moving average price is $21.54 and its two-hundred day moving average price is $21.56. Avanos Medical, Inc. has a 52-week low of $17.39 and a 52-week high of $25.36. The stock has a market capitalization of $879.62 million, a P/E ratio of 56.35 and a beta of 0.92.

Analyst Ratings Changes

Separately, StockNews.com downgraded Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 3rd.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.